TONIX PHARMACEUTICALS, INC.
|TONIX PHARMACEUTICALS, INC. Patent applications|
|Patent application number||Title||Published|
|20140336264||EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.||11-13-2014|
|20140212486||ISOMETHEPTENE ISOMER - The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I),||07-31-2014|
|20120232159||Methods and Compositions for Treating Depression using Cyclobenzaprine - The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug.||09-13-2012|
|20120101154||COMPOSITIONS AND METHODS FOR INCREASING COMPLIANCE WITH THERAPIES USING ALDEHYDE DEHYDROGENASE INHIBITORS AND TREATING ALCOHOLISM - Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.||04-26-2012|
|20110319389||METHODS AND COMPOSITIONS FOR TREATING FATIGUE ASSOCIATED WITH DISORDERED SLEEP USING VERY LOW DOSE CYCLOBENZAPRINE - The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.||12-29-2011|
|20110124656||Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine - The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.||05-26-2011|
Patent applications by TONIX PHARMACEUTICALS, INC.